Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard J Hargreaves

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
"It Ain't Over 'til It's Over" (a) -The Search for Treatments and Cures for Alzheimer's DiseaseRichard J Hargreaves
Headache|January 24, 2009
10 years of rizatriptanRichard J Hargreaves
Neurobiology of Disease|September 24, 2013
Translational PET imaging researchRichard J Hargreaves, Eugenii A Rabiner
Current Pain and Headache Reports|September 17, 2013
Why does sleep stop migraine?Marcelo E Bigal, Richard J Hargreaves
The Journal of Pharmacology and Experimental Therapeutics|May 17, 2003
A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathyYou-Tang Shen, Joseph J Lynch, Richard J Hargreaves, et al.
Journal of Cardiovascular Pharmacology|February 19, 2010
Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteriesJoseph J Lynch, Christopher P Regan, Lars Edvinsson, et al.
Headache|January 24, 2009
Ten years of rizatriptan: from development to clinical science and future directionsRichard J Hargreaves, Chris R Lines, Alan M Rapoport, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 2009
Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypesNancy A Ator, John R Atack, Richard J Hargreaves, et al.
Human Psychopharmacology|October 21, 2014
Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorderWilliam A Ball, Duane B Snavely, Richard J Hargreaves, et al.
CNS Drugs|October 13, 2018
From LBR-101 to Fremanezumab for MigraineMarcelo E Bigal, Alan M Rapoport, Stephen D Silberstein, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
ACS Medicinal Chemistry Letters|June 6, 2014
"It Ain't Over 'til It's Over" (a) -The Search for Treatments and Cures for Alzheimer's DiseaseRichard J Hargreaves
Headache|January 24, 2009
10 years of rizatriptanRichard J Hargreaves
Neurobiology of Disease|September 24, 2013
Translational PET imaging researchRichard J Hargreaves, Eugenii A Rabiner
Current Pain and Headache Reports|September 17, 2013
Why does sleep stop migraine?Marcelo E Bigal, Richard J Hargreaves
The Journal of Pharmacology and Experimental Therapeutics|May 17, 2003
A growth hormone secretagogue prevents ischemic-induced mortality independently of the growth hormone pathway in dogs with chronic dilated cardiomyopathyYou-Tang Shen, Joseph J Lynch, Richard J Hargreaves, et al.
Journal of Cardiovascular Pharmacology|February 19, 2010
Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteriesJoseph J Lynch, Christopher P Regan, Lars Edvinsson, et al.
Headache|January 24, 2009
Ten years of rizatriptan: from development to clinical science and future directionsRichard J Hargreaves, Chris R Lines, Alan M Rapoport, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 2009
Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypesNancy A Ator, John R Atack, Richard J Hargreaves, et al.
Human Psychopharmacology|October 21, 2014
Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorderWilliam A Ball, Duane B Snavely, Richard J Hargreaves, et al.
CNS Drugs|October 13, 2018
From LBR-101 to Fremanezumab for MigraineMarcelo E Bigal, Alan M Rapoport, Stephen D Silberstein, et al.
Pageof 4